Choosing between single-base, RIP and array routes
The three routes are not grades of one another — each reports a different resolution. This article covers what each route delivers, the questions that decide between them, and the readings that go wrong most often.
01What this review answers
A route is a level of resolution. Single-base sequencing resolves a modification at an individual nucleotide and reports how much of that position is modified; RIP-sequencing enriches modified fragments and reports enrichment across transcript regions; arrays report modification levels across a defined set of transcripts without resolving positions.
Most method confusion comes from skipping that distinction. Where the conclusion names a nucleotide, only the single-base route can carry it. Where the first question is which transcripts differ across a large sample set, an enrichment or array pass reaches that answer sooner than site-level work on every sample.
Below: what each route reports, how to decide between them, and the boundaries that belong in the interpretation.
02What each route reports
The routes differ in resolution and in scale, and the difference is not one of quality. Each is the right instrument for the question it was built to answer.
| Route | What it reports | Resolution | The question it answers first |
|---|---|---|---|
| Single-base sequencing | Where a modification sits and the modification ratio at that position | Individual nucleotide | Does the conclusion name a position? |
| RIP-sequencing | Where a modification is enriched across transcripts, read against an input control | Transcript region | Which transcripts or regions differ across a sample set? |
| Modification arrays | Modification level across a defined set of transcripts in parallel | Transcript set | Which targets are worth following up? |
A fourth readout sits alongside the three. Mass spectrometry measures the nucleoside itself rather than a sequencing library, which makes it an independent check on what any of the routes reports.
03How to choose
Four questions usually settle the route before any method detail needs comparing.
- Does the conclusion name a site? A claim about a specific nucleotide belongs on the single-base line. Enrichment can point at the transcript, but it does not name the position.
- How many samples are in the comparison? Large sample sets are more practical on the enrichment or array routes, which is why those are normally the first pass and site-level work follows on the targets that matter.
- Is an antibody acceptable in the design? RIP-sequencing depends on an antibody step. Where that dependency is unwanted, most of the single-base line is antibody-free; the exceptions are m3C-IP-seq and O8G-miSeq. Arrays read hybridization rather than an immunoprecipitation.
- Is an independent quantification needed? Where a modification level has to be confirmed outside a sequencing readout, mass spectrometry measures the nucleoside itself.
04Limits and common misreadings
- An enrichment result is not a site call. A peak spans a region, and reading it as a position overstates what the assay resolved.
- An array result does not localise. Arrays report levels across a defined set of transcripts and do not place a modification on a nucleotide.
- Resolution does not transfer. Setting a site-level table beside a region-level profile compares two different quantities, even when both come from the same samples.
- The routes are normally combined. Screening, profiling and site-level work answer different parts of one study, so planning them together keeps the samples and the comparisons aligned.
06FAQ
Can a RIP-seq profile be used to claim a specific modified site?
No. The signal comes from enriched fragments, so it localises to a region rather than to a nucleotide. A claim about a specific position needs a single-base method run on the same material, since setting a site-level table beside a region-level profile compares two different quantities even when both come from the same samples.
Which route should a first project use?
If the answer has to name a position, the single-base line is the route that carries it. If the first question is which transcripts differ across a large sample set, an enrichment or array pass reaches that answer sooner, and it narrows the site-level work to the targets that matter.
Do the routes accept different sample types?
No. All three routes accept total RNA, cells, tissue or blood. What differs between them is the preparation detail given on each service page, not the material that can be submitted, so the choice between them is decided by the resolution the conclusion needs.
Is one route more reliable than another?
They measure different quantities, so reliability is not compared across them. The useful question is whether the readout matches the claim being made, which is what the resolution column above settles. Reading a region-level profile as a position is the misreading that distinction exists to prevent.